Machine Learning-Based Prediction of Invisible Intraprostatic Prostate Cancer Lesions on 68Ga-PSMA-11 PET/CT in Patients with Primary Prostate Cancer

Zhilong Yi
The Seventh Affiliated Hospital, Sun Yat-sen University

Siqi Hu
The Third Affiliated Hospital of Sun Yet-sun University Department of Nephrology

Xiaofeng Lin
The Seventh Affiliated Hospital, Sun Yat-sen University

Qiong Zou
The Third Affiliated Hospital of Sun Yet-sun University

MinHong Zou
The Third Affiliated Hospital of Sun Yet-sun University

Zhanlei Zhang
Sun Yat-Sen Memorial Hospital

Lei Xu
The Third Affiliated Hospital of Sun Yat-sun University

Ningyi Jiang (jiangny@mail.sysu.edu.cn)
The Seventh Affiliated Hospital, Sun Yat-Sen University
https://orcid.org/0000-0002-2468-6153

Yong Zhang
The Third Affiliated Hospital of Sun Yat-sun University

Research Article

Keywords: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Radiomics, Machine Learning, Area Under Curve, Prostate-Specific Antigen

DOI: https://doi.org/10.21203/rs.3.rs-868542/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Purpose** $^{68}$Ga-PSMA PET/CT has high specificity and sensitivity for the detection of both intraprostatic tumor focal lesions and metastasis. However, approximately 10% of primary prostate cancer are invisible on PSMA-PET (exhibit no or minimal uptake). In this work, we investigated whether machine learning-based radiomics models derived from PSMA-PET images could predict invisible intraprostatic lesions on $^{68}$Ga-PSMA-11 PET in patients with primary prostate cancer.

**Methods** In this retrospective study, patients with or without prostate cancer who underwent $^{68}$Ga-PSMA PET/CT and presented negative on PSMA-PET image at either of two different institutions were included: institution 1 (between 2017 to 2020) for the training set and institution 2 (between 2019 to 2020) for the external test set. Three random forest (RF) models were built using selected features extract from standard PET images, delayed PET images, and both standard and delayed PET images. Then, subsequent 10-fold cross-validation was performed. In the test phase, the three RF models and PSA density (PSAD, cut-off value: 0.15ng/ml/ml) were tested with the external test set. The area under the receiver operating characteristic curve (AUC) was calculated for the models and PSAD. The AUCs of the radiomics model and PSAD were compared.

**Results** A total of 64 patients (39 with prostate cancer and 25 with benign prostate disease) were in the training set, and 36 (21 with prostate cancer and 15 with benign prostate disease) were in the test set. The average AUCs of the three RF models from 10-fold cross-validation were 0.87 (95% CI: 0.72, 1.00), 0.86 (95% CI: 0.63, 1.00) and 0.91 (95% CI: 0.69, 1.00), respectively. In the test set, the AUCs of the three trained RF models and PSAD were 0.903 (95% CI: 0.830, 0.975), 0.856 (95% CI: 0.748, 0.964), 0.925 (95% CI:0.838, 1.00), and 0.662 (95% CI: 0.510, 0.813). The AUCs of the three radiomics models were higher than that of PSAD (0.903, 0.856 and 0.925 vs 0.662, respectively; $P = .007$, $P = .045$ and $P = .005$, respectively).

**Conclusion** Random forest models developed by $^{68}$Ga-PSMA-11 PET-based radiomics features were proven useful for accurate prediction of invisible intraprostatic lesion on $^{68}$Ga-PSMA-11 PET in patients with primary prostate cancer and showed better diagnostic performance compared with PSAD.

**Introduction**

Prostate cancer (PCa) is the second leading cause of cancer death in men [1]. The worldwide incidence rates significantly increased during the last decade, most likely due to the wider application of prostate-specific antigen (PSA) screening [1]. Early detection of primary disease and its metastases is highly relevant in terms of prognosis and therapy management. Systematic transrectal ultrasound-guided biopsy (TRUS-GB) is widely used for the diagnosis of PCa in men who present with an elevated serum PSA [2, 3]. However, this approach is responsible for the underdetection of clinically significant PCa due to potential sampling error and interobserver variability; also, this method leads to the overdetection of
clinically insignificant cancer [4-6]. Moreover, it can cause procedure-related complications, including bleeding, pain and infection [2, 3].

Imaging methods can help determine which men with elevated PSA continue to undergo biopsy, which may reduce unnecessary biopsies and improve diagnostic accuracy [2, 3]. MRI is a well-established, highly accurate imaging modality. Combining prostate-specific antigen density (PSAD) with the MRI PI-RADS score may help define patients who need biopsy[3]. Ahmed et al. [2] reported that using multiparameter MRI (mpMRI) might allow 27% of patients to avoid a primary biopsy and diagnose 5% fewer clinically insignificant cancers. However, mpMRI is known to have low specificity in very low-risk patients and poor sensitivity in small intraprostatic tumors [3, 7, 8]. Panebianco et al. [9] presented that small foci and disease within the central gland may not be easily identified by mpMRI, and up to 35% of clinically insignificant PCa may be invisible to mpMRI. $^{68}$Ga prostate-specific membrane antigen positron emission tomography/computed tomography ($^{68}$Ga-PSMA PET/CT), as a new imaging method based on molecular analysis rather than morphological or physiological analysis, has a higher specificity and sensitivity for detection of both intraprostatic tumor focal lesions and metastasis compared with MRI, as well as of tumor foci to characterize the bilateral and multifocal disease [10-12]. Recently, $^{68}$Ga-PSMA PET/CT showed satisfactory results to aid decision-making by confirming or eliminating the further need for biopsies [12-14]. However, according to the literature, approximately 10% of primary PCa are negative on PSMA-PET (exhibit no or minimal uptake) despite high PSA levels [15-19], which may be due to small lesion size or lesion configuration [15]. In literature by Zamboglou et al. [15], their result indicated that the incidence of invisible PCa lesions was not correlated with patients’ basic clinical parameters or basic SUV parameters derived from gross tumor volume PET(GTV-PET), and 40% of invisible lesions were clinically significant (ISUP>1) PCa. How to deal with prostate cancer patients with negative findings on PSMA-PET images remains a challenge. Thus, there is a need for simple, non-invasive, and accurate methods of detecting invisible intraprostatic lesions on $^{68}$Ga-PSMA-11 PET in patients with primary prostate cancer.

Radiomics analysis, in which large numbers of features are extracted from images, including signal intensity, histogram-based features, textural features and transform filter-based features, has recently gained attention as a promising method for tumor biology characterization, prognosis prediction, and assisting in decision making [20, 21]. Compared with previous ways that process medical images as pictures for visual inspection, radiomics introduces a new way to mine the information contained in the medical images [22]. Recently, radiomics combined with machine learning in MRI and PET/CT demonstrated the potential feasibility for prostate cancer detection, risk assessment and prognosis prediction [15, 23-28]. Therefore, we hypothesized that machine learning models based on radiomics features extracted from $^{68}$Ga-PSMA-11 PET images might allow a comprehensive assessment of imaging features associated with invisible intraprostatic lesions and improve prediction ability.

Therefore, in light of the potential of combining PET/CT imaging and machine learning-based radiomics analysis, the purpose of our study was to develop and validate radiomics models for predicting invisible
intraprostatic lesions on $^{68}$Ga-PSMA-11 PET in patients with primary prostate cancer.

**Materials And Methods**

The institutional review board approved this retrospective study, and the requirement to obtain informed consent was waived.

**Study Population**

We retrospectively analyzed 306 patients who underwent $^{68}$Ga-PSMA-11 PET/CT between 2017 and 2020 at institutions 1 (The third affiliated hospital of Sun Yat-Sen University, Guangzhou, China) and 132 patients who underwent $^{68}$Ga-PSMA-11 PET/CT between 2019 and 2020 at institution 2 (Sun Yat-Sen memorial hospital, Guangzhou, China). Two nuclear radiologists (N.Y.J and Y.Z, with more than 10 years of experience at prostate PET/CT interpretation), using Horos software (v4.0.0, https://www.horosproject.org), independently evaluated the image data and included negative PSMA-PET image cases according to previously described criteria: the prostate without focal radiotracer uptake higher than that of surrounding prostate tissue in more than one image slice on standard and delayed PET images (for an example of a patient without visualization of the primary PCa tumor, see Figure 1) [15, 18, 24, 29]. Any disagreement was resolved by consensus. To avoid recall bias, these two nuclear radiologists did not participate in the PET analysis session. Inclusion criteria were: (1) prostate cancers or non-PCas were confirmed by biopsy or postoperative pathology, non-PCAs with the initial biopsy were further confirmed by follow-up for at least 6 months by PSA screening, MRI, second biopsy, or transurethral resection prostate (TURP) with the histopathologic examination; prostate cancers were pathology confirmed diagnosis of prostate adenocarcinoma. (2) a time-interval between $^{68}$Ga-PSMA-11 PET/CT scans and histopathological examination less than 14 days. The exclusion criteria included the following: (1) history of other malignancies; (2) $^{68}$Ga-PSMA PET/CT examination was performed after anti-tumor pharmacotherapy or surgery; (3) incomplete clinical, laboratory, pathological, or imaging data unavailable or with poor quality.

Patients identified at institutions 1 and 2 were assigned to the training and external test sets, respectively (Figure 2).

**$^{68}$Ga-PSMA PET/CT acquisition and image reconstruction**

$^{68}$Ga-PSMA PET/CT images were obtained using a PET/CT scanner (Discovery Elite, GE Healthcare, Milwaukee, WI) at institution 1 and a Biograph mCT PET/CT scanner (Siemens Healthcare, Erlangen, Germany) at institution 2, according to standard clinical scanning protocols. Images were acquired after intravenous administering of 1.8-2.2 MBq/kg $^{68}$Ga-PSMA-11. A diagnostic and non-enhanced CT scan (120 kVp, 120-150mAs) was performed first using a slice thickness of 3.0 mm. Then, whole-body PET imaging (2–4 min per bed position, 6–7 beds) from skull to the mid thigh was conducted at one hour(standard), and pelvic PET imaging (2–4 min per bed position, 1–2 beds) from the superior anterior
spine to thighs was conducted at 2-2.5 hours (delayed) after intravenous injection, respectively. PET acquisition was performed in a three-dimensional (3D) model, and data were corrected with attenuation, scatter, random coincidences and decay correction. PET images were attenuated-corrected using CT data. At institution 1, PET reconstruction was performed using an ordered subset expectation maximization (OSEM) and setting a spectrum of parameters, for instance, VUE Point FX module (GE healthcare), 3 iterations, 24 subsets, matrix 192x192, slice thickness of 3.27mm, pixel size 3.65x3.65x3.27 mm³ with a filter (6.4mm), and all necessary correction methods including attenuation and scatter correction. At institution 2, acquired PET images were reconstructed using a TrueX+TOF (ultraHD-PET) with 3 iterations and 21 subsets, and a Gaussian filter of 5.0mm into an image matrix size of 200x200 with a voxel size of 4.1x4.1x3.0mm³, and all necessary correction methods including attenuation and scatter correction. Subsequently, PET images were converted into SUV units by normalizing the activity concentration to the dosage of ⁶⁸Ga-PSMA-11 injected and the patient body weight after decay correction.

Development of the Radiomics Models

Tissue segmentation. PET images and axial CT images were loaded into ITK-SNAP software, version 3.8.0 (open source, http://www.itksnap.org) for segmentation [30]. The masks of prostatic gland volume were refined by two nuclear radiologists (Z.L.Y and S.Q.H, with 5 and 3 years of experience, respectively) who were blind to the clinical data. Three-dimensional ROIs of the left and right half-prostate glands were manually segmented on PSMA-PET images under consideration of the corresponding CT scan (Figure 3).

Radiomics feature extraction. ⁶⁸Ga-PSMA-11 PET-based radiomics features were derived by using the Pyradiomics package (version 3.0.1, https://github.com/Radiomics/pyradiomics) for Python (version 3.6.1). A total of 3562 quantitative features (1781 features for each phase) were extracted from the prostate ROIs on standard and delayed PET images, respectively. For each phase PET image, the 1781 features consisted of 107 features (including 14 morphology features, 18 original first-order features, 16 gray level size zone matrix (GLSZM) features, 14 gray level dependence matrix (GLDM) features, 5 neighboring gray level dependence matrix (NGLDM) features, 24 gray level co-occurrence matrix (GLCM) features, 16 gray level run length matrix (GLRLM) features) were calculated on the original images; 744 features were calculated on the wavelet-filtered images; 465 features were calculated on the Laplacian of Gaussian (LoG)-filtered images; 186 features on the square-filtered images; 93 features on the gradient-filtered images; 93 features on the exponential-filtered images.

Feature Selection and Radiomics model development. In our study, the number of radiomics features was large, while the number of cases was relatively small. To mitigate model overfitting and potentially improve generalizability, the classic minimum redundancy maximum relevance (mRMR) method (https://github.com/smazzanti/mrmm) was used to select the 10 most useful predictive features with $R^2$ difference. This algorithm ensures the selection of highly relevant features to actual classes while controlling for the redundancy within the selected features. The mRMR algorithm has been proven effective in both radiomics and genomics studies, where a small subset of features must be chosen out
of the thousands of features [24, 26, 31]. Then, we constructed a machine learning framework in Python 3.6.1 using Scikit-learn library 0.23.2 (https://scikit-learn.org/stable/whats_new/v0.23.html#version-0.23-2). The random forest (RF) machine learning model was applied using the selected features. The hyperparameters of the RF models were optimized within each training set using the GridSearchCV (Scikit-learn library 0.23.2) method with 10-fold cross-validation iteration. The average AUC score, the average precision score, the average recall score, the average accuracy score and the average F1 score obtained after 10-fold cross-validation were provided to evaluate the performance of the trained RF models for the training set. The hyperparameters are provided in Supplementary Table 1. The overall workflow of the radiomics model development is presented in Figure 3.

### External test and Comparison of different machine learning models and PSA Density

The three trained RF models were applied to the external test set. The performance of the models was evaluated by the receiver operator characteristic curve (ROC) analysis. The best cut-off point for each model was estimated by using the Youden index to calculate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).

Prostate-specific antigen density (PSAD) was selected as the single factor for comparison with the radiomics model. PSAD was calculated as total PSA (ng/ml) divided by prostate volume (ml). Based on a previous literature review [3], the PSAD cut-off value was set at 0.15ng/ml/ml. In this study, the prostate volume was calculated by CT-based prolate ellipsoid formula (three diameters measured directly on the CT images, volume = width × height × length × π/6) [32, 33].

### Statistical Analysis

The differences regarding the demographic data between the training and external test sets were assessed. Statistical analyses were performed with the R statistical software (version 4.0.5; R Foundation for Statistical Computing). Continuous variables were tested by Student's T-test or Mann–Whitney U test between two groups. The Chi-square test or Fisher's exact test, where appropriate, was applied for comparing categorical variables. The AUCs of the radiomics models were compared with that of the PSAD using the DeLong method [34].

### Results

#### Patient Clinical Characteristics

A total of 100 patients were included in this study. At institution 1, 64 patients (mean age ± standard deviation, 61.9 years ± 8.8) were identified and assigned to the training set; delayed imaging was performed in 46 of these patients. Thirty-six patients (mean age ± standard deviation, 67.6 years ± 8.8) from institution 2 were identified and assigned to the external test set, and 25 of these patients underwent delayed scans. Clinical characteristics of training (n=64) and external test (n=36) sets are summarized in Table 1. In the training set, 39 patients were diagnosed with prostate cancer and 25 patients with benign
prostate disease, including benign prostate hyperplasia (n=7), chronic inflammation (n=1) and BPH with chronic inflammation (n=17). In the external test set, 21 patients were diagnosed with prostate cancer. The benign prostate disease of 15 patients included benign prostate hyperplasia (n=8), chronic inflammation (n=1) and BPH with chronic inflammation (n=6). The distributions of age, tPSA, PSAD, Gleason score and ISUP grade were not significantly different between training and external test set.

Radiomics model development

Development and Testing of the Radiomics RF Model based on Standard PET images

A total of 1781 radiomics features were extracted from the prostate ROIs on standard PET images. The 10 most useful predictive features of standard PET images selected by the mMRM method were one original first order features, 3 wavelet-based features, 4 Laplacian of Gaussian–based features, one squareroot-based feature and one logarithm-based feature. A cluster heatmap of these radiomics features was generated by means of agglomerative hierarchical clustering to visualize the differences between PCa and non-PCa groups and the association between the found clusters of subjects and features. (Figure 4.a).

The average AUC, recall score, accuracy score and the F1 score of the RF model based on standard PET images from 10-fold cross validation were 0.87 (95% CI: 0.72, 1.00), 0.90 (95% CI: 0.70, 1.00), 0.82 (95% CI: 0.60,1.00), 0.84 (95% CI: 0.68, 1.00) and 0.84 (95% CI: 0.68, 1.00), respectively.

Development and Testing of the Radiomics Model based on Delayed PET images

A total of 1781 radiomics features were extracted from the prostate ROIs on delayed PET images. The 10 most useful predictive features of delayed PET images selected by the mRMR method were 5 wavelet-based, one Laplacian of Gaussian–based features, one square-based feature, one exponential-based feature, one logarithm-based feature and one gradient-based feature. A cluster heatmap of these radiomics features was generated by means of agglomerative hierarchical clustering to visualize the differences between PCa and non-PCa groups and the association between the found clusters of subjects and features. (Figure 4.b).

The average AUC, precision score, recall score, accuracy score and the F1 score of the RF model based on standard PET images and delayed PET images from 10-fold cross validation were 0.86 (95% CI: 0.63, 1.00), 0.87 (95% CI: 0.63, 1.00), 0.81 (95% CI: 0.57, 1.00), 0.80 (95% CI: 0.53, 1.00) and 0.79 (95% CI: 0.51, 1.00), respectively.

Development and Testing of the Radiomics Model based on Standard and Delayed PET images

To develop the RF model based on standard and delayed PET images, we used both the 10 most useful predictive features of standard PET images and the 10 most useful predictive features of delayed PET images selected by the mRMR method.
The average AUC, precision score, recall score, accuracy score and the F1 score of the RF model based on standard PET images and delayed PET images from 10-fold cross validation were 0.91 (95% CI: 0.69, 1.00), 0.91 (95% CI: 0.65, 1.00), 0.93 (95% CI: 0.75, 1.00), 0.88 (95% CI: 0.65, 1.00) and 0.87 (95% CI: 0.61, 1.00), respectively.

The performance of trained radiomics RF models based on standard PET images, delayed PET images, and both standard and delayed PET images from 10-fold cross-validation were summarized in Table 2.

Comparison of the Radiomics Models and PSAD in the External Test Set

In the external test set, the AUCs of trained RF model based on standard PET images, delayed PET images, and both standard and delayed PET images were 0.903 (95% CI: 0.830, 0.975), 0.856 (95% CI: 0.748, 0.964) and 0.925 (95% CI: 0.838, 1.000), respectively. The sensitivity, specificity, accuracy, PPV and NPV were 0.816 (95% CI: 0.657, 0.923), 0.767 (95% CI: 0.577, 0.901), 0.794 (95% CI: 0.679, 0.883), 0.816 (95% CI: 0.648, 0.923) and 0.767 (95% CI: 0.587, 0.901) for RF model based on standard PET images; 0.750 (95% CI: 0.509, 0.913), 0.846 (95% CI: 0.651, 0.956), 0.804 (95% CI: 0.661, 0.906), 0.789 (95% CI: 0.560, 0.930) and 0.814 (95% CI: 0.603, 0.946) for RF model based on delayed PET images; and 0.850 (95% CI: 0.621, 0.968), 0.885 (95% CI: 0.698, 0.976), 0.870 (95% CI: 0.737, 0.951), 0.850 (95% CI: 0.631, 0.968) and 0.885 (95% CI: 0.689, 0.976) for RF model based on both standard and delayed PET images, respectively.

The AUC, sensitivity, specificity, accuracy, PPV and NPV of PSAD (cutoff value, 0.15ng/ml/ml) in the external test set were 0.662 (95% CI: 0.510, 0.813), 0.857 (95% CI: 0.637, 0.970), 0.467 (95% CI: 0.213, 0.734), 0.694 (95% CI: 0.519, 0.837), 0.692 (95% CI: 0.410, 0.923) and 0.700 (95% CI: 0.405, 0.880).

The AUCs of radiomics RF model based on standard PET images, delayed PET images, and both standard and delayed PET images were higher than that of PSAD (0.903, 0.856 and 0.925 vs 0.662, respectively; \( P = .007, P = .045 \) and \( P = .005 \), respectively).

The diagnostic performance of the three radiomics models and the use of PSAD (cut-off value, 0.15ng/ml/ml) in the external test set were summarized in Table 3. The ROC curves of the three radiomics models and PSAD were shown in Figure 5.

Discussion

In this study, we developed three radiomics RF models (based on standard PET images, delayed PET images, and both standard and delayed PET images, respectively) by allowing for the prediction of invisible intraprostatic lesions on \( ^{68} \)Ga-PSMA-11 PET in patients with primary prostate cancer. The three radiomics RF models developed by using the training cohort data enabled the discrimination in the external test cohort with areas under the curve of 0.856-0.925 and accuracies of 79.4%-87.0%. Although there were no differences among the AUCs of the three radiomics RF models, the RF model based on both standard and delayed PET images demonstrated excellent diagnostic performance with a test set (AUC,
0.925; sensitivity, 85.0%; specificity, 88.5%; accuracy, 87.0%; PPV, 85.0%; NPV, 88.5%). In addition, the three radiomics RF models showed better diagnostic performance than PSAD ( P< 0.05). These findings suggest that predictive machine learning-based radiomics models could assist in predicting invisible intraprostatic lesions on $^{68}$Ga-PSMA-11 PET in patients with primary prostate cancer.

Previous studies evaluated the feasibility of radiomics models based on T2-weight images, diffusion-weighted images and ADC images for differentiating non-cancerous prostate from prostate cancer and histopathological prediction grade of PCa [23, 25, 26, 35], as well as $^{68}$Ga-PSMA-11 PET images [15]. Wibmer et al. [23] suggested that radiomics features extracted from T2WI and ADC maps were helpful for differentiating non-cancerous and cancerous prostate tissue, and tumor Energy and Entropy on ADC maps correlated with Gleason score. In recent literature, Xu et al. [35] developed a prediction model using biparametric MRI radiomics features that showed high preoperative diagnostic performance (AUC=0.92) in discriminating between benign and malignant prostate lesions. However, Bonekamp et al. [25] demonstrated that radiomics machine learning had comparable but not better performance than mean ADC assessment differentiation of benign versus malignant prostate lesions. Although these methods yielded promising results, the subjects were all based on visually visible lesions on MRI. The above research results may not be applicable to the prediction of small, invisible intraprostatic cancer lesions. Moreover, none of these studies were validated in separate external test data sets, leaving the generalizability of their results unproven. Gong et al. [26] constructed radiomics models by delineating the whole prostate gland on T2-weight images and diffusion-weighted images, which can noninvasively identify high-grade PCa before the operation. However, this study only analyzed patients with obvious prostate cancer lesions on MRI, and a separate external test data set was also lacked. In a recent report by Zamboglou et al. [15], PSMA-PET-derived radiomics features derived from $^{68}$Ga-PSMA-11 PET images were recently reported helpful in visually unknown PCa detection (sensitivities ≥ 0.8 in the validation cohort). In their study, non-PCa tissue was defined as the subtraction volumes between the prostatic gland and PCa tumors in $^{68}$Ga-PSMA-11 PET based on pathological tissue slices from PCa patients. However, radiomics features need to be further studied whether differences exist between the prostate tissue in the non-tumor area of prostate cancer patients and the prostate tissue in non-tumor patients. In addition, unlike our training set that included patients with and without PCa, the authors extracted and analyzed radiomics features from a training set with a small sample size (n=20), and only patients with PCa were enrolled. The accuracies of the two selected radiomics features (local binary pattern (LBP) size-zone non-uniformity normalized and LBP small-area emphasis) for prediction visually undetectable intraprostatic tumor lesions in $^{68}$Ga-PSMA-11 PET images (area under the curve were 0.80 and 0.83 in half prostate level analysis, respectively) were slightly lower than ours, although a head-to-head comparison is needed to compare these results.

Among the 20 radiomics features selected using the mRMR method for developing RF models, the original_firstorder_MeanAbsoluteDeviation feature extracted from standard PET images was the only feature directly related to the standard intake value (SUV). In this study, original_firstorder_MeanAbsoluteDeviation was the average distance of all image values mean array,
which can be used to assess the variability of metabolic activity [36]. The original firstorder_MeanAbsoluteDeviation feature in the prostate cancer subset was higher than that in the non-PCa subset in both cohorts in our study, which may reflect that the uptake of $^{68}$Ga-PSMA-11 in the prostate gland with cancerous tissue was more nonuniformity than the non-malignant prostate. Previous studies suggested that the deviation of SUV was helpful for differentiating solitary lung adenocarcinoma from tuberculosis [37], in agreement with our results. Five skewness and kurtosis features applied with Wavelet, Gradient, Squareroot and Exponential transform filters (wavelet_HHH_firstorder_Kurtosis, wavelet_LHL_firstorder_Skewness, gradient_firstorder_Median, squareroot_firstorder_Skewness, and exponential_firstorder_Skewness) extracted from delayed PET images were also selected for modeling. Skewness and kurtosis are more sophisticated histogram-based features, which can be used to describe heterogeneity [38]. Previous literature had shown promising results using skewness and kurtosis features for differentiating different types of malignant tumors and predicting response to therapy in various tumor types [39, 40]. Mean values of these features in the prostate cancer subset were lower than the non-PCa subset. This similar finding may also reflect more heterogeneity uptake of $^{68}$Ga-PSMA-11 in prostate with cancerous tissue in delayed PET images. The remaining 14 texture radiomics features extracted from standard and delayed PET images for modeling include 3 Gray-Level Cooccurrence Matrix (GLCM) features, 5 Gray-Level Size Zone Matrix (GLSZM) features, 2 Gray-Level Run-length Matrix(GLRLM) features and 4 Gray-Level Dependence Matrix (GLDM) features associated with different filters Wavelet, LoG, Squareroot and Logarithm transform filters. These texture features calculate the nonuniformity of the gray levels or the length of the homogeneous zones, reflecting the heterogeneity within the delineated area. Kuess et al. [41] indicated that GLCM-based features extracted from mpMRI data could be used to differentiate between tumor and healthy tissue in the peripheral zone of the prostate. Sun et al. [27] reported that GLCM, GLSZM and GLRLM-based features extracted from T2-weighting images were helpful for the stratification of prostate tumor aggressiveness. In a study by Mohamed et al. [42], GLDM-based features extracted from ultrasound images were beneficial for prostate cancer diagnosis and aiding biopsy planning. Our results are consistent with those of the studies mentioned above. However, in the above studies, the radiomics features were extracted from MR or ultrasound images, which contained less information on the expression of specific PSMA molecules closely related to prostate cancer compared with $^{68}$Ga-PSMA PET images. Moreover, the value of radiomics features based on the whole prostate in differentiating with or without cancer components has not been studied. In this study, GLSZM, GLCM and GLDM-based features were the most important features of the three radiomics RF models (Supplementary Table 2), respectively, which may support that prostate gland with cancer component were more heterogeneous than those without malignancy on both standard and delayed PET images.

PSAD, a well-established predictor of clinically significant PCa, has been showing to be a useful predictor for selecting patients who need to undergo mpMRI and to optimize the diagnostic pathway for patients presenting with negative mpMRI (PI-RADS 1–2) [3, 43, 44]. Combining PSAD with the PI-RADS score may help define patients who need biopsy [3]. In this study, the diagnostic performance of PSAD in the external test sets was additionally compared to radiomics RF models. In the external test set of our study,
the AUC of PSAD was 0.662, which slightly underperformed in comparison with a previous report (AUC: 0.717) [45]. Compared to PSAD, the three radiomics RF models (AUCs: 0.856–0.925) developed in this study showed better diagnostic efficiency.

Furthermore, half-glandular segmentation was used for delineation. Previous radiomics studies of prostate cancer mainly extracted and analyzed features based on delineating the tumor [23, 25, 26, 35]. However, when we encounter smaller invisible cancerous lesions in the prostate, using this method will lead to a considerable challenge in determining the interest to be delineated. Recently, Gong et al. [26] developed radiomics models based on delineated the whole prostate gland and showed good encouraging performances for noninvasively distinguishing high-grade PCa. Zamboglou et al. [15] proved that radiomics features derived from $^{68}$Ga-PSMA-11 PET images based on half-glandular segmentation were helpful for predicting invisible PCa lesions. The above results demonstrated the feasibility of using segmentation methods based on half-glandular or full-glandular segmentation. In addition, compared with tumor segmentation, half-glandular or full-glandular segmentation may be more convenient for applying automatic or semi-automatic segmentation [46].

Our study has some limitations: (1) Although this study was a two-centers design, the relatively small sample size in both the training set and external test set may compromise the model's generalization ability and affect its sensitivity and specificity. A multicenter study with a big sample size to validate the ability of the radiomics model in this study should be applied in further research. (2) This study is retrospective with possible selection bias. The proportion of PCa patients enrolled with high-grade (GS >7) PCa was more than those with lower-grade (GS ≤7) PCa, which may cause the model to potentially overestimate the risk of patients with low-grade (GS ≤7) PCa. (3) To calculated the PSAD value, we measured the diameters of the prostate gland on abdomen CT images. Although CT had better spatial resolution than MRI and ultrasound images, previous studies mainly used MRI and ultrasound to estimate the volume of the prostate gland [32, 33].

Conclusion

In conclusion, random forest models developed by $^{68}$Ga-PSMA-11 PET-based radiomics features showed good predictive performance. Radiomics machine learning models may be a promising non-invasive method for accurate prediction of invisible intraprostatic lesion on $^{68}$Ga-PSMA-11 PET in patients with primary prostate cancer.

Declarations

Funding information

This study was supported by the Medical Science and Technology Research Fund Project of Guangdong (A2019526) and the Guangzhou Science & Technology Project (201802020033).

Conflicts of interest
No conflict of interest exits in the submission of this manuscript.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability

The code applied during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

All authors contributed to the study conception and design. The research was designed by Ningyi Jiang and Yong Zhang. Material preparation, data collection, and analysis were performed by Zhilong Yi, Siqi Hu, Xiaofeng Lin, Qiong Zou, MinHong Zou, Zhanlei Zhang and Lei Xu. The first draft of the manuscript was written by Zhilong Yi and reviewed by Ningyi Jiang and Yong Zhang. All authors commented on previous versions of the manuscript. All authors read and approved the nal manuscript.

Ethics approval

The institutional review board approved this retrospective study, and the requirement to obtain informed consent was waived.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Acknowledgments

The authors would like to acknowledge all the co-workers who participated in this study.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34. http://dx.doi.org/10.3322/caac.21551

2. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815-22. http://dx.doi.org/10.1016/S0140-6736(16)32401-1
1. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79:243-62. http://dx.doi.org/10.1016/j.eururo.2020.09.042

2. Schouten MG, van der Leest M, Pokorny M, Hoogenboom M, Barentsz JO, Thompson LC, et al. Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naive Men? Eur Urol. 2017;71:896-903. http://dx.doi.org/10.1016/j.eururo.2016.12.006

3. Ukimura O, Coleman JA, de la Taille A, Emberton M, Epstein JI, Freedland SJ, et al. Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol. 2013;63:214-30. http://dx.doi.org/10.1016/j.eururo.2012.09.033

4. Abraham NE, Mendhiratta N, Taneja SS. Patterns of repeat prostate biopsy in contemporary clinical practice. J Urol. 2015;193:1178-84. http://dx.doi.org/10.1016/j.juro.2014.10.084

5. Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol. 2015;67:569-76. http://dx.doi.org/10.1016/j.eururo.2014.08.079

6. Borofsky S, George AK, Gaur S, Bernardo M, Greer MD, Mertan FV, et al. What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. Radiology. 2018;286:186-95. http://dx.doi.org/10.1148/radiol.2017152877

7. Panebianco V, Barchetti G, Simone G, Del Monte M, Ciardi A, Grompone MD, et al. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next? Eur Urol. 2018;74:48-54. http://dx.doi.org/10.1016/j.eururo.2018.03.007

8. Donato P, Roberts MJ, Morton A, Kyle S, Coughlin G, Esler R, et al. Improved specificity with (68)Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. Eur J Nucl Med Mol Imaging. 2019;46:186-95. http://dx.doi.org/10.1007/s00259-018-4160-7

9. Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, et al. The Impact of (68)Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med. 2018;59:82-8. http://dx.doi.org/10.2967/jnumed.117.197160

10. Zhang LL, Li WC, Xu Z, Jiang N, Zang SM, Xu LW, et al. (68)Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided
biopsy: a prospective randomized single-centre study. Eur J Nucl Med Mol Imaging. 2021;48:483-92. http://dx.doi.org/10.1007/s00259-020-04863-2

15. Zamboglou C, Bettermann AS, Gratzke C, Mix M, Ruf J, Kiefer S, et al. Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in (68)GaPSMA-11 PET images of patients with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:1987-97. http://dx.doi.org/10.1007/s00259-020-05111-3

16. Zhang J, Shao S, Wu P, Liu D, Yang B, Han D, et al. Diagnostic performance of (68)Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms. Eur J Nucl Med Mol Imaging. 2019;46:908-20. http://dx.doi.org/10.1007/s00259-018-4255-1

17. Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, et al. Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124:401-7. http://dx.doi.org/10.1111/bju.14828

18. Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. (68)Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44:941-9. http://dx.doi.org/10.1007/s00259-017-3631-6

19. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016;195:1436-43. http://dx.doi.org/10.1016/j.juro.2015.12.025

20. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2016;278:563-77. http://dx.doi.org/10.1148/radiol.2015151169

21. Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749-62. http://dx.doi.org/10.1038/nrclinonc.2017.141

22. Liu Z, Wang S, Dong D, Wei J, Fang C, Zhou X, et al. The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges. Theranostics. 2019;9:1303-22. http://dx.doi.org/10.7150/thno.30309

23. Wibmer A, Hricak H, Gondo T, Matsumoto K, Veeraraghavan H, Fehr D, et al. Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur Radiol. 2015;25:2840-50. http://dx.doi.org/10.1007/s00330-015-3701-8

24. Zamboglou C, Carles M, Fechter T, Kiefer S, Reichel K, Fassbender TF, et al. Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. Theranostics. 2019;9:2595-605. http://dx.doi.org/10.7150/thno.32376
25. Bonekamp D, Kohl S, Wiesenerth M, Schelb P, Radtke JP, Gotz M, et al. Radiomic Machine Learning for Characterization of Prostate Lesions with MRI: Comparison to ADC Values. Radiology. 2018;289:128-37. http://dx.doi.org/10.1148/radiol.2018173064

26. Gong L, Xu M, Fang M, Zou J, Yang S, Yu X, et al. Noninvasive Prediction of High-Grade Prostate Cancer via Biparametric MRI Radiomics. J Magn Reson Imaging. 2020;52:1102-9. http://dx.doi.org/10.1002/jmri.27132

27. Sun Y, Reynolds HM, Wraith D, Williams S, Finnegan ME, Mitchell C, et al. Automatic stratification of prostate tumour aggressiveness using multiparametric MRI: a horizontal comparison of texture features. Acta Oncol. 2019;58:1118-26. http://dx.doi.org/10.1080/0284186X.2019.1598576

28. Alongi P, Stefano A, Comelli A, Laudicella R, Scalis S, Arnone G, et al. Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients. Eur Radiol. 2021;31:4595-605. http://dx.doi.org/10.1007/s00330-020-07617-8

29. Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging. 2016;16:14. http://dx.doi.org/10.1186/s40644-016-0072-6

30. Yushkevich PA, Gerig G. ITK-SNAP: An Intractive Medical Image Segmentation Tool to Meet the Need for Expert-Guided Segmentation of Complex Medical Images. IEEE Pulse. 2017;8:54-7. http://dx.doi.org/10.1109/MPUL.2017.2701493

31. Ding C, Peng H. Minimum redundancy feature selection from microarray gene expression data. J Bioinform Comput Biol. 2005;3:185-205. http://dx.doi.org/10.1142/s0219720005001004

32. Varkarakis I, Zarkadoulias A, Bourdoumis A, Chatzidarellis E, Antoniou N, Deliveliotis C. Measurement of PSA density by 3 imaging modalities and its correlation with the PSA density of radical prostatectomy specimen. Urol Oncol. 2013;31:1038-42. http://dx.doi.org/10.1016/j.urolonc.2011.11.033

33. Caglic I, Sushentsev N, Gnanapragasam VJ, Sala E, Shaida N, Koo BC, et al. MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. Eur Radiol. 2021;31:2696-705. http://dx.doi.org/10.1007/s00330-020-07336-0

34. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-45.

35. Xu M, Fang M, Zou J, Yang S, Yu D, Zhong L, et al. Using biparametric MRI radiomics signature to differentiate between benign and malignant prostate lesions. Eur J Radiol. 2019;114:38-44. http://dx.doi.org/10.1016/j.ejrad.2019.02.032

36. Mostafapour S, Gholamiankhah F, Dadgar H, Arabi H, Zaidi H. Feasibility of Deep Learning-Guided Attenuation and Scatter Correction of Whole-Body 68Ga-PSMA PET Studies in the Image Domain. Clin Nucl Med. 2021;46:609-15. http://dx.doi.org/10.1097/RLU.0000000000003585

37. Hu Y, Zhao X, Zhang J, Han J, Dai M. Value of (18)F-FDG PET/CT radiomic features to distinguish solitary lung adenocarcinoma from tuberculosis. Eur J Nucl Med Mol Imaging. 2021;48:231-40.
38. Mayerhoefer ME, Materka A, Langs G, Haggstrom I, Szczypinski P, Gibbs P, et al. Introduction to Radiomics. J Nucl Med. 2020;61:488-95. http://dx.doi.org/10.2967/jnumed.118.222893
39. Bang JI, Ha S, Kang SB, Lee KW, Lee HS, Kim JS, et al. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F]FDG PET/CT scans in locally advanced rectal cancer. Eur J Nucl Med Mol Imaging. 2016;43:422-31. http://dx.doi.org/10.1007/s00259-015-3180-9
40. Chandarana H, Rosenkrantz AB, Mussi TC, Kim S, Ahmad AA, Raj SD, et al. Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer. Radiology. 2012;265:790-8. http://dx.doi.org/10.1148/radiol.12111281
41. Khalvati F, Wong A, Haider MA. Automated prostate cancer detection via comprehensive multi-parametric magnetic resonance imaging texture feature models. BMC Med Imaging. 2015;15:27. http://dx.doi.org/10.1186/s12880-015-0069-9
42. Mohamed SS, Salama MM, Kamel M, El-Saadany EF, Rizkalla K, Chin J. Prostate cancer multi-feature analysis using trans-rectal ultrasound images. Phys Med Biol. 2005;50:N175-85. http://dx.doi.org/10.1088/0031-9155/50/15/N02
43. Falagario UG, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, et al. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). Eur Urol Oncol. 2020 http://dx.doi.org/10.1016/j.euo.2020.08.014
44. Alberts AR, Roobol MJ, Drost FH, van Leenders GJ, Bokhorst LP, Bangma CH, et al. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. BJU Int. 2017;120:511-9. http://dx.doi.org/10.1111/bju.13836
45. Zheng XY, Xie LP, Wang YY, Ding W, Yang K, Shen HF, et al. The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. J Cancer Res Clin Oncol. 2008;134:1207-10. http://dx.doi.org/10.1007/s00432-008-0400-8
46. Bulman JC, Toth R, Patel AD, Bloch BN, McMahon CJ, Ngo L, et al. Automated computer-derived prostate volumes from MR imaging data: comparison with radiologist-derived MR imaging and pathologic specimen volumes. Radiology. 2012;262:144-51. http://dx.doi.org/10.1148/radiol.11110266

Tables

Table 1. Clinical Characteristics in the Training and External Test Set
### Characteristic

|                          | Training Set (n=64) | External Test Set (n=36) | P value |
|--------------------------|---------------------|--------------------------|---------|
|                          | Non-PCa (n=25)      | PCa (n=39)               |         |
| Age (years)              | 67.1 ± 9.3          | 69.0 ± 9.4               | 0.536 * |
| tPSA (ng/ml)             | 8.0 (4.9-13.3)      | 23.81 (10.91-77.87)     | 0.796 ξ |
| PSAD (ng/ml/ml)          | 0.13 (0.09-0.23)    | 0.53 (0.16-1.29)         | 0.636 ξ |
| Gleason score            |                     |                          | 0.807 § |
| ≤ 7                      | 19 (48.7%)          | 8 (38.1%)                |         |
| ≥ 7                      | 20 (51.3%)          | 13 (61.9%)               |         |
| ISUP grade               |                     |                          | 0.430 § |
| ≤ 2                      | 10 (25.6%)          | 6 (28.5%)                |         |
| ≥ 2                      | 29 (74.4%)          | 15 (71.5%)               |         |

Note.- Normally distributed continuous variables are represented as mean ± variance; abnormally distributed continuous variables are represented as median (interquartile range, IQR); categorical variables are represented as the number of cases (percentage%).

PCa = prostate cancer; tPSA = total prostate specific antigen; PSAD = prostate specific antigen density.

* Rough P values were calculated using the Student’s test between patients in the training and external test sets.

ξ Rough P values were calculated using the Mann-Whitney U test between patients in the training set and external test set.

§ Rough P values were calculated using the Chi-square test between PCa patients in the training set and external test set.

Table 2. Performance of Trained RF models with 10-fold Cross-validation in Training Sets
| Parameters | RF model based on standard PET images | RF model based on delayed PET images | RF model based on standard and delayed PET images |
|-----------|--------------------------------------|--------------------------------------|-----------------------------------------------|
| AUC score | 0.87 [0.72, 1.00]                     | 0.86 [0.63, 1.00]                    | 0.91 [0.69, 1.00]                              |
| Precision score | 0.90 [0.70, 1.00]                   | 0.87 [0.63, 1.00]                    | 0.91 [0.65, 1.00]                              |
| Recall score | 0.82 [0.60, 1.00]                    | 0.81 [0.57, 1.00]                    | 0.93 [0.75, 1.00]                              |
| Accuracy score | 0.84 [0.68, 1.00]                   | 0.80 [0.53, 1.00]                    | 0.88 [0.65, 1.00]                              |
| f1 score | 0.84 [0.68, 1.00]                     | 0.79 [0.51, 1.00]                    | 0.87 [0.61, 1.00]                              |

Note.—Data in square brackets are 95% CIs of mean values.

RF models = random forest models.

### Table 3. Performance of Trained RF models in External Test Sets

| Parameter | RF model based on standard PET images | RF model based on delayed PET images | RF model based on standard and delayed PET images | PSAD [Cutoff value, 0.15ng/ml/ml] |
|-----------|--------------------------------------|--------------------------------------|-----------------------------------------------|----------------------------------|
| AUC       | 0.903 [0.830, 0.975]                  | 0.856 [0.748, 0.964]                 | 0.925 [0.838, 1.000]                          | 0.662 [0.510, 0.813]             |
| Sensitivity | 0.816 (31/38) [0.657, 0.923]       | 0.750 (15/20) [0.509, 0.913]        | 0.850 (17/20) [0.621, 0.968]                  | 0.857 (18/21) [0.637, 0.970]     |
| Specificity | 0.767 (23/30) [0.577, 0.901]       | 0.846 (22/26) [0.651, 0.956]        | 0.885 (23/26) [0.698, 0.976]                  | 0.467 (7/15) [0.213, 0.734]      |
| Accuracy   | 0.794 (54/68) [0.679, 0.883]        | 0.804 (37/46) [0.661, 0.906]        | 0.870 (40/46) [0.737, 0.951]                  | 0.694 (25/36) [0.519, 0.837]     |
| PPV        | 0.816 (31/38) [0.648, 0.923]        | 0.789 (15/19) [0.560, 0.930]        | 0.850 (17/20) [0.631, 0.968]                  | 0.692 (18/26) [0.410, 0.923]     |
| NPV        | 0.767 (23/31) [0.587, 0.901]        | 0.814 (22/27) [0.603, 0.946]        | 0.885 (23/26) [0.689, 0.976]                  | 0.700 (7/10) [0.405, 0.880]      |

Note.—Data in parentheses are numbers of the half-prostate gland delineated, with 95% CIs in square brackets.

RF models = random forest models; AUC = area under the receiver operating characteristic curve; PPV = positive predictive value; NPV = negative predictive value.
Figure 1

Example of a patient without visualization of the primary prostate cancer on 68Ga-PSMA-11 PET/CT. 68Ga-PSMA-11 PET/CT with maximum-intensity projection (a. anteroposterior, b. lateral), fused PET/CT (c) and axial PET (d) images of a 62-year-old patient with postoperative pathology-proven PCa (GS 4+3) and a PSA value of 15.66 ng/ml. On fused PET/CT images and PET images alone, no focal radiotracer uptake is higher than that of surrounding prostate tissue.
Inclusion criteria
(1) invisible mass in prostate on PET/CT
(2) Prostate cancer: pathology confirmed diagnosis of prostate adenocarcinoma
(3) Benign prostatic disease: negative cases with the initial biopsy were further confirmed by follow-up for at least 6 months by PSA screening, MRI, second biopsy, or trans-urethral resection prostate (TURP) with histopathologic examination.
(4) A time-interval between $^{68}$Ga-PSMA-11 PET/CT scans and histopathological examination less than 14 days.

Excluded criteria
(1) $^{68}$Ga-PSMA PET/CT examination was performed after chemotherapy or surgery
(2) History of other malignancies
(3) Incomplete clinical, laboratory, pathological, or imaging data unavailable or with poor quality

Training set
n=64

Benign prostatic disease
n=25
(1h: L-lobes=25, R-lobes=25)
(Delayed: L-lobes=17, R-lobes=17)

Prostate cancer
n=39
(1h: L-lobes=30, R-lobes=38)
(Delayed: L-lobes=25, R-lobes=29)

External test set
n=36

Benign prostatic disease
n=15
(1h: L-lobes=15, R-lobes=15)
(Delayed: L-lobes=13, R-lobes=13)

Prostate cancer
n=21
(1h: L-lobes=17, R-lobes=21)
(Delayed: L-lobes=8, R-lobes=12)

Figure 2
Flow diagram of the study Flow diagram of the study.

167 original images features
744 wavelet-filtered features
495 log2-filtered features
185 square-root-filtered features
93 gradient-channel features
53 exponential-filtered features
50 logarithm-filtered features

Feature selection
Random Forest (RF) models
With 10-fold cross validation

ROC Curves

Imaging Acquisition
Segmentation
Feature Extraction
Modeling Building
External Test
Figure 3

Workflow of the development and testing of radiomics models. First, lesions were manually segmented on axial PET images under the corresponding CT scans for radiomics analysis. Second, a total of 1781 radiomics features were extracted. Third, the 10 most relevant features were selected in the training phase with classic minimum redundancy maximum relevance (mRMR). Three random forest (RF) models were built and validated with the 10-fold cross-validation method. Fourth, in the test phase, the RF model was tested with an external test set. ROC = receiver operating characteristic.

![Heatmap of the 10 most relevant radiomics features extracted from standard PET image (a) and delayed PET image (b) for differentiating between PCa and non-PCa prostate. glcm = gray level co-occurrence matrix, gldm = gray level dependence matrix, glrlm = gray level run length matrix, glszm = gray level size zone matrix, H = high-pass filter, L = low-pass filter, 3D = three-dimensional, Imc2 = informational measure of correlation (IMC). 2. HHH, LHH, LHL, LLH, and LLL indicate wavelet transform bands in the X, Y, and Z axis, respectively.]

Figure 4

Heatmap of the most relevant radiomics features extracted from standard PET image (a) and delayed PET image (b) for differentiating between PCa and non-PCa prostate. glcm = gray level co-occurrence matrix, gldm = gray level dependence matrix, glrlm = gray level run length matrix, glszm = gray level size zone matrix, H = high-pass filter, L = low-pass filter, 3D = three-dimensional, Imc2 = informational measure of correlation (IMC). 2. HHH, LHH, LHL, LLH, and LLL indicate wavelet transform bands in the X, Y, and Z axis, respectively.
Figure 5

ROC curves of RF models and PSAD Curves show radiomics RF models based on standard PET image, delayed PET image, both standard and delayed PET images, and PSAD (cut-off value: 0.15ng/ml/ml) by using ROC curve analysis for differentiation of PCa from non-PCa prostate. Details of the AUCs and 95% CIs of each index are shown in the Results section and Table 3. RF= random forest, PSAD = PSA density.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryMaterial.docx